Latest Indian Guidelines for Dyslipidemia Management: A Biochemist’s Perspective
The recent lipid management guidelines emphasize using low density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (non-HDL-C), and apo B levels as treatment targets. Out of these, LDL-C is the primary target of lipid management, non-HDL-C is the co-primary and ApoB is the seco...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Jaypee Brothers Medical Publisher
2024-12-01
|
| Series: | Indian Journal of Medical Biochemistry |
| Subjects: | |
| Online Access: | https://www.ijmb.in/doi/IJMB/pdf/10.5005/jp-journals-10054-0244 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The recent lipid management guidelines emphasize using low density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (non-HDL-C), and apo B levels as treatment targets. Out of these, LDL-C is the primary target of lipid management, non-HDL-C is the co-primary and ApoB is the secondary target. One-time estimation of lipoprotein(a) is sufficient presently to assess risk in view of the lack of specific drugs targeting it. Triglyceride levels ≥150 mg/dL in fasting and ≥175 mg/dL in non-fasting samples are considered risk modifiers for atherosclerotic cardiovascular disease. Lipid profile estimation in a non-fasting sample is considered good enough to manage a dyslipidemia patient. The inclusion of risk group-specific target range of lipid profile in biochemistry report format shall be more informative and helpful in ensuring better patient compliance. |
|---|---|
| ISSN: | 0972-1207 2456-5164 |